We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
- Authors
Huiping Li; Jiang Liu; Jianing Chen; Huiyun Wang; Linbin Yang; Fei Chen; Siting Fan; Jing Wang; Bin Shao; Dong Yin; Musheng Zeng; Mengfeng Li; Jun Li; Fengxi Su; Qiang Liu; Herui Yao; Shicheng Su; Erwei Song
- Abstract
Trastuzumab is a standard treatment for HER2-positive (HER2+) breast cancer, but some patients are refractory to the therapy. MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear. Using miRNA microarray, we identify 13 differentially expressed miRNAs in the serum of HER2+ MBC patients with distinct response to trastuzumab, and four miRNAs are selected to construct a signature to predict survival using LASSO model. Further, our data show that miR-940 is mainly released from the tumor cells and miR-451a, miR-16-5p and miR-17-3p are mainly from the immune cells. All these four miRNAs directly target signaling molecules that play crucial roles in regulating trastuzumab resistance. In summary, we develop a serum-based miRNA signature that potentially predicts the therapeutic benefit of trastuzumab for HER2+ MBC patients and warrants future validation in prospective clinical trials.
- Publication
Nature Communications, 2018, Vol 9, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-018-03537-w